Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 6/20 | 0.47 |
| ▸ | DUT | P33316 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.36 |
| ▸ | TK2 | O00142 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2278653 | 0.90 | BCHE (0.41) | TOP2ADUTBCHETK1TK2 | |
| SCHEMBL2278650 | 0.90 | BCHE (0.41) | TOP2ADUTBCHETK1TK2 | |
| SCHEMBL2284865 | 0.87 | TOP2A (0.57) | TOP2ADUTBCHETK1HDAC1 | |
| SCHEMBL10046512 | 0.85 | TOP2A (0.47) | TOP2ADUTBCHETK1HDAC1 | |
| SCHEMBL30848702 | 0.83 | LMNA (0.47) | TOP2ADUTBCHETK1HDAC1 | |
| SCHEMBL14217396 | 0.81 | TK1 (0.44) | BCHETK1TK2 | |
| SCHEMBL888191 | 0.80 | TOP2A (0.53) | TOP2ADUTTK1HDAC1TK2 | |
| SCHEMBL12762675 | 0.80 | TOP2A (0.53) | TOP2ADUTTK1HDAC1TK2 | |
| SCHEMBL12570187 | 0.80 | TOP2A (0.53) | TOP2ADUTTK1HDAC1TK2 | |
| SCHEMBL2284831 | 0.80 | TOP2A (0.39) | TOP2ADUTBCHEHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835625-B2 | Propargyl substituted nucleoside compounds and methods | APPLIED BIOSYSTEMS, LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-7998706-B2 | Pyrimidine nucleobases | APPLIED BIOSYSTEMS, LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | Life Technologies Corporation (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | PNP, NT5C3B, NUDT1 | TOP2A 255/4885DUT 5/4885BCHE 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.